ABSTRACT
Introduction
Chronic obstructive pulmonary disease (COPD) is an extensive, preventable and treatable disease that is associated with the chronic inflammatory response increasing in airways and lungs against harmful gases and particles, and usually characterized by a progressive and persistent airflow restriction (1) . Becoming the 3rd cause of death in the entire world, it is responsible from 5.5 % of all deaths (2) . Although the role of genetic risk factors in COPD development could not be enlightened very well yet; smoking, biomass fuel usage, working in dusty and smoky places are the most important risk factors (3) .
In comparison to normal lung tissue, the number of apoptotic endothelial and epithelial cells increased with COPD. Apoptotic conductions are started through specific ligands such as Fas ligand, Tumor Necrosis Factor alpha (TNF alpha) and TNF-related apoptosis inducing ligand (TRAIL). With 2 proapoptotic (TRAIL-R1 and TRAIL-R2) and 2 nonapoptotic (TRAIL-R3 and TRAIL-R4) receptors, TRAIL is a member of TNF family. TRAIL receptor 1, 2 and 3 protein levels were found significantly high in patients with emphysema (4) . But the TRAIL receptor 1 (Death receptor 4, DR4) role of COPD is not known for pathogenesis. To that end, we planned investigating DR4 polymorphism G422A (rs6557634), C626G (rs20575) A683C (rs20576) for COPD in our study.
Materials and Method

Participants
The protocol was approved by the regional ethical committee and made according to the principles of Helsinki Declaration. 97 COPD patients, who were diagnosed through GOLD guideline standards, have been analyzed. The onset of illness, the character, place, ache time and history of illness, the accompanying symptoms and the medication reports have been examined in the analysis. 97 COPD patients from the archive records of the Chest Diseases Department of Muğla Sitki Kocman University Medical Faculty, who do not have any other chronic disease, have been included in the study. A control group has been constituted from 158 healthy individuals that live in the same geographical region.
Genotyping
Genotyping determination DNA was extracted from peripheral blood leukocytes;PCR was performed in a 25-μL volume with 100 ng DNA, 100μm dNTPs, 20 pmol of each primer, 1.5 mM MgCl2, 1 x PCRbuffer with (NH4)2SO4 (Fermentas, Vilnius, Lithuania), 10% DMSO and 2 U Taq DNA polymerase (Fermentas, Vilnius, Lithuania). Amplification was performed on an automated Thermal Cycler (Techne Flexigene, Cambridge, UK). These genetic polymorphisms were determined by fragment separation at 120 V for 40-50 minutes on a 3.5% agarose gel containing 0.5 mg/mL ethidium bromide. A 100-bp DNA Ladder (Fermentas Vilnius, Lithuania) was used as a size standard for each gel lane. The gel was visualised under UV light using a gel electrophoresis visualising system (Vilber Lourmat).
Statistical analysis
Genotype distribution within the groups of cases and controls was compared with values predicted by HardyWeinberg equilibrium using the x2test. Hardy-Weinberg equilibrium, based on allele frequencies, was verifed with the formula: p2 +2pq+q2 =1. The relationships between genotypes and alleles and risk assesment were determined by obtaining the odds ratios (ORs) and 95% confidence intervals (CI) through a logistic regression method. We used SPSS version 15.0 (SPSS Inc., Chicago, IL) to run the statistical analysis. x2 values with a probability (p) value < 0.05 were considered statistically signifcant.
Results
We evaluated 97 consecutive COPD patients (18 women, 79 men; mean age 65±10 years) from the database of Mugla Sitki Kocman University Medical Faculty, Department of Chest Disease. 158 (91 women, 67 men; mean age 68±5 years) unrelated, age-and sex-matched, healthy controls were selected from the same geographic area.
The genotype and allele frequencies for rs6557634, rs20575 and rs20576 polymorphisms in cases and controls are shown in Tables 1, 2 and 3. The observed genotype counts were compared to those expected for cases and controls under Hardy-Weinberg equilibrium. To determine whether there was a population substructure in the COPD and control groups, we evaluated Hardy-Weinberg equilibrium for the rs6557634, rs20575 and rs20576 polymorphisms. We found that rs20575 genotype frequencies were in Hardy-Weinberg equilibrium in COPD group (p=0.10) and in the control group (p=0.12) ( Table  2 ). The genotype frequencies of rs20576 were in HardyWeinberg equilibrium in the control group (p=0.65) and in COPD group (p=0.06) ( Table 3 ). The genotype frequencies of rs6557634 were in Hardy-Weinberg equilibrium in the control group (p=0.06) and skewed in COPD group (p=0.02) ( Table 1) . We did not observe a significant association between genotypes of any of the 3 analysed polymorphisms and risk for COPD (Table 4) .
Discussion
COPD is an important global health problem ever increasing in the entire world and especially in the developing countries. It is estimated that there are 210 million COPD patients in the world, and a great part of them (70-80 %) were not diagnosed (5). Early diagnosis looms large in removing the risk factors and accordingly preventing the progression of the disease.
COPD is a disease resultant in the interaction between genetic sensitivity and exposure to environmental stimuli (6). The most known risk factor for COPD is the deficiency of alpha-1 antitrypsin (AAT) and it is seen in 1-2 % of all patients. In case of smoking, AAT deficiency increases panlobular emphysema development. Complex diseases like COPD arise usually out of gene -environment interaction. Therefore, many candidate genes that could be related to the development of the disease were investigated widely. TNF-alpha, MMP-9, alpha 1-antikimotripsin (SERPINA 3), glutathione s-transferaz (GST), vitamin binding protein, microsomal epoxide hydrolase (mEH) are the genes that were investigated most. However, inconsistent results were obtained in different study populations (3).
In our study, we analyzed G422A (rs6557634), C626G (rs20575) and A683C (rs20576) polymorphisms in DR4 gene. As far as we know, this is the first study, where DR4 gene polymorphism has been investigated in patients with COPD. We found that DR4 gen rs20576 polymorphism may be related with COPD disease. Although COPD disease is a frequent health problem, TRAIL's role in COPD pathogenesis is not known clearly yet. Besides normal cells, it is known that TRAIL triggered apoptosis in transformed cells (7) . It was shown that TRIAL concentration increased in viral pulmonary infections and affected the response to treatment. Besides, TRAIL is upregulated in airways of the patients with asthma (8). Morissette et al. found TRAIL receptor 1, 2 and 3 protein levels high in the serums of the patients with emphysema (4). TRAIL reseptör 1 (DR4) consists of two extracellu- C: Cytosine, G: Guanine lar cysteine-rich, ligand-binding pseudorepeats (50s and 90s loops), one single transmembrane helix as well as the apoptosis-triggering cytoplasmic death domain (9) . Many other studies have previouslyshown that rs6557634, rs20575 and rs20576 in the DR4 gene are important for cancer (10) (11) (12) .These studies to be realized with low cost through easily accessible equipment supports the usability of these genotypes and alleles for a more precise and objective diagnosis for COPD.
In the end of this study, we found an association rs20576 polymorphism of DR4 gene and decreased risk of COPD disease. Any association between DR4 gene and COPD could not be shown in any previous study. In the more prospective studies, the DR4 gene expressions and mutations should be analyzed with bigger COPD patients group. Moreover, additional studies are needed for clarifying DR4 gene's role in the pathogenesis of COPD. A: Adenine, C: Cytosine
